Skip to main content
. 2021 Nov 25;13(23):5939. doi: 10.3390/cancers13235939

Figure 1.

Figure 1

AZD2858 is cytotoxic in glioma cell lines at micromolar concentrations and induces mitotic defects at submicromolar concentrations. (A) The established cell lines U251 and U87 and patient-derived glioma stem cell-like cell lines GBM1 and GBM4 were treated with 10-fold dilutions of AZD2858 in triplicate. Cell viability was assessed by MTT at day 3 post treatment. (B) Normal brain cells including normal human astrocytes (NHA) and neural progenitor cells (NP1) were treated with 10-fold dilutions of AZD2858 in triplicate. Cell viability was assessed by MTT at day 3 post treatment. (C) The established cell lines U87 and U251 and the patient-derived glioma stem cell-like cell line GBM4 were treated with 1 µM or a concentration range (0.01–1 µM) of AZD2858 and imaged over 72 h or over 1 week by live cell imaging. Representative stills are shown from live cell imaging movies of the patient-derived stem cell-like cell line GBM4 mock-treated with DMSO (top panel) or treated with AZD2858 at 500 nM. This dose was chosen as no cytotoxic effects were observed on normal progenitor cells or NHA and to illustrate specific effects on mitosis in the GBM cell line. Arrows indicate mitotic cells during the duration of mitosis. Images were taken from AVI movies generated with the Incucyte imaging system. Magnification = 10×.